Posted 07 December 2013 - 07:49 PM
I have been using this stack for the past month now. The combo provides a clear smooth flow of mood and clarity. However it has also provided me occasionally with a brain fog and I cannot distill the reason why. Another reason I am stopping this combo is because I see no memory improvement at all. I know that it take 24 weeks to conclude anything meaningful. I have read up on this entire thread as well as the pubmed articles showing memory improvement and dendritic spine growth in rats. I believe that is fascinating. The first souvenaid human trial yielded positive results. However a subsequent bigger and better designed trial showed absolutely no improvement in patients memory which is a bit disappointing. I might cycle this combo for the mood enhancement properties but I will reserve my own doubts regarding memory enhancement.
Has anyone noticed a significant boost in recall memory? Declarative memory? It really hasn't helped me at all in med school.
The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer's disease.
AuthorsShah RC, et al. Show all Journal
Alzheimers Res Ther. 2013 Nov 26;5(6):59. [Epub ahead of print]
Affiliation
Abstract
INTRODUCTION: Souvenaid® containing Fortasyn® Connect is a medical food designed to support synapse synthesis in persons with Alzheimer's disease (AD). Fortasyn Connect includes precursors (uridine monophosphate; choline; phospholipids; eicosopentaenoic acid; docosahexaenoic acid) and cofactors (vitamins E, C, B12, and B6; folic acid; selenium) for the formation of neuronal membranes. Whether Souvenaid slows cognitive decline in treated persons with mild-to-moderate AD has not been addressed.
METHODS: In a 24-week, double-masked clinical trial at 48 clinical centers, 527 participants taking AD medications [52% women, mean age 76.7 years (Standard Deviation, SD = 8.2), and mean Mini-Mental State Examination score 19.5 (SD = 3.1, range 14--24)] were randomized 1:1 to daily, 125-mL (125 kcal), oral intake of the active product (Souvenaid) or an iso-caloric control. The primary outcome of cognition was assessed by the 11-item Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog). Compliance was calculated from daily diary recordings of product intake. Statistical analyses were performed using mixed models for repeated measures.
RESULTS: Cognitive performance as assessed by ADAS-cog showed decline over time in both control and active study groups, with no significant difference between study groups (difference =0.37 points, Standard Error, SE = 0.57, p = 0.513). No group differences in adverse event rates were found and no clinically relevant differences in blood safety parameters were noted. Overall compliance was high (94.1% [active] and 94.5% [control]), which was confirmed by significant changes in blood (nutritional) biomarkers.
CONCLUSIONS: Add-on intake of Souvenaid during 24 weeks did not slow cognitive decline in persons treated for mild-to-moderate AD. Souvenaid was well tolerated in combination with standard care AD medications.Trial registration: Dutch Trial Register number: NTR1683.
[Health claims for medical foods].
Authors
Katan MB.
Journal
Ned Tijdschr Geneeskd. 2013;157(24):A6471. Article in Dutch.
Affiliation
Vrije Universiteit Amsterdam, afd. Gezondheidswetenschappen, Amsterdam, the Netherlands. katan99@falw.vu.nl
Abstract
Souvenaid (Nutricia, Zoetermeer, the Netherlands) is a medical food for the dietary management of early Alzheimer's disease. The mix of nutrients in this drink is suggested to have a beneficial effect on cognitive function; such implicit health claims for medical foods are not checked by government agencies. Souvenaid has been investigated in three clinical trials. The first trial showed that Souvenaid produced a significant improvement in delayed verbal recall, but not in other psychological tests. The second and largest trial showed no effect on any outcome. The third trial showed no significant effect at 12 or 24 weeks, but a significant difference in the 24-week time course of the composite memory score. None of these outcomes was clearly specified as a primary outcome at trial registration. In conclusion, there is no convincing proof that Souvenaid benefits cognitive function. Better scrutiny of the efficacy of medical foods is warranted.
PMID 23759182 [PubMed - indexed for MEDLINE]